Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-

[1]  A. Tomelleri,et al.  Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. , 2020, Seminars in arthritis and rheumatism.

[2]  T. Mimori,et al.  The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study , 2019, Rheumatology International.

[3]  J. Raynauld,et al.  Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry , 2019, Arthritis Research & Therapy.

[4]  H. Yoshikawa,et al.  Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study- , 2019, PloS one.

[5]  H. Yoshikawa,et al.  Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study , 2019, Arthritis Research & Therapy.

[6]  X. Mariette,et al.  Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study , 2019, Clinical Rheumatology.

[7]  K. Aoyagi,et al.  Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study , 2019, Rheumatology.

[8]  K. Ohmura,et al.  Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study , 2018, Arthritis Research & Therapy.

[9]  M. Genovese,et al.  Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial , 2018, The Journal of Rheumatology.

[10]  H. Yoshikawa,et al.  Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study- , 2018, PloS one.

[11]  A. Barton,et al.  Rheumatoid arthritis , 2018, Nature Reviews Disease Primers.

[12]  A. Ogata,et al.  A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period , 2018, Modern rheumatology.

[13]  P. Sarzi-Puttini,et al.  Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry , 2017, Clinical Rheumatology.

[14]  T. Takeuchi,et al.  Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study , 2017, RMD Open.

[15]  M. Genovese,et al.  Low immunogenicity of tocilizumab in patients with rheumatoid arthritis , 2016, Annals of the rheumatic diseases.

[16]  J. Kremer,et al.  Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry , 2016, Arthritis Research & Therapy.

[17]  J. Jansen,et al.  Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. , 2016, Clinical therapeutics.

[18]  Y. Kawahito.  [Guidelines for the management of rheumatoid arthritis]. , 2016, Nihon rinsho. Japanese journal of clinical medicine.

[19]  Marcus John Beasley,et al.  Twelve‐Year Retention Rate of First‐Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real‐Life Data From a Local Registry , 2016, Arthritis care & research.

[20]  M. Matucci-Cerinic,et al.  Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. , 2016, Seminars in arthritis and rheumatism.

[21]  T. Takeuchi,et al.  Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis , 2016, Clinical Rheumatology.

[22]  H. Bliddal,et al.  Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. , 2015, Rheumatology.

[23]  C. Gabay,et al.  Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. , 2015, Rheumatology.

[24]  J. Smolen,et al.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges , 2015, Nature Reviews Rheumatology.

[25]  P. Meroni,et al.  Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. , 2014, Rheumatology.

[26]  H. Olsson,et al.  Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab , 2013, Annals of the rheumatic diseases.

[27]  M. Neurath,et al.  How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy , 2013, Nature Medicine.

[28]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[29]  J. Kremer,et al.  A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry , 2012, Annals of the rheumatic diseases.

[30]  T. Spector,et al.  Pain reporting at different body sites is explained by a single underlying genetic factor , 2010, Rheumatology.

[31]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[32]  N. Miyasaka,et al.  Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis , 2009, Modern rheumatology.

[33]  C. Gabay,et al.  Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[34]  N. Miyasaka,et al.  Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis , 2007, Modern rheumatology.

[35]  F. Wolfe,et al.  Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues , 2004, Annals of the rheumatic diseases.

[36]  B. Hogan.  Ten years on , 1991, Nature.

[37]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[38]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[39]  M. Neovius,et al.  Ten years with biologics: to whom do data on effectiveness and safety apply? , 2011, Rheumatology.

[40]  I. Christensen,et al.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. , 2010, Arthritis and rheumatism.

[41]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[42]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.